For research use only. Not for therapeutic Use.
(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective JAK3 inhibitor (IC50=144.8 nM) extracted from patent US20150158864A1, example 68[1].
| Catalog Number | I045701 |
| CAS Number | 1792180-79-0 |
| Synonyms | 1-[(2R,5S)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one |
| Molecular Formula | C15H19N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m1/s1 |
| InChIKey | CBRJPFGIXUFMTM-MNOVXSKESA-N |
| SMILES | CC1CCC(CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3 |
| Reference | [1]. Atli Thorarensen, et al. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides. US20150158864A1. |
